Want to see DE:BNN full AI Analyst Report?
Top Page
B.R.A.I.N. Biotechnology Research and Information Network
(XETRA:BNN)
Select Model
Select Model
Rating:45Neutral
Price Target:
€3.00
▲(9.09% Upside)
Action:Reiterated
Date:09/10/26
The score is primarily constrained by weak financial performance—persistent losses, ongoing cash burn, and especially negative shareholders’ equity—indicating elevated funding/solvency risk. Technicals are moderately supportive with price above key moving averages but momentum is neutral. Valuation is difficult to support due to negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Improving Gross Margin
The improvement in gross margin indicates better economics on the company’s revenue base than in the prior annual periods. If sustained, this could provide greater capacity to cover operating costs and support future profitability, although operating losses remain substantial.
Negative Factors
Negative Revenue Growth
Declining revenue indicates weakening commercial momentum and reduces the operating base available to absorb fixed costs. Unless the trend reverses, lower scale can make it harder to leverage the improved gross margin, fund research activities internally, and move toward sustainable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving Gross Margin
The improvement in gross margin indicates better economics on the company’s revenue base than in the prior annual periods. If sustained, this could provide greater capacity to cover operating costs and support future profitability, although operating losses remain substantial.
Read all positive factors
B.R.A.I.N. Biotechnology Research and Information Network (BNN) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€59.64M
Dividend YieldN/A
Average Volume (3M)3.93K
Price to Earnings (P/E)―
Beta (1Y)-0.03
Revenue GrowthN/A
EPS GrowthN/A
CountryDE
Employees280
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.66
Shares Outstanding21,847,494
10 Day Avg. Volume3,410
30 Day Avg. Volume3,930
Financial Highlights & Ratios
PEG Ratio-0.69
Price to Book (P/B)25.87
Price to Sales (P/S)0.96
P/FCF Ratio-4.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)€55.10M
B.R.A.I.N. Biotechnology Research and Information Network Business Overview & Revenue Model
Company Description
Headquartered in Zwingenberg, Germany, and founded in 1993, BRAIN Biotech AG (renamed from B.R.A.I.N. Biotechnology Research and Information Network AG in April 2021) specializes in the discovery, development, production, and commercialization of ...
B.R.A.I.N. Biotechnology Research and Information Network Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
18
Very Negative
Cash Flow
21
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 59.03M | 49.62M | 54.63M | 55.34M | 49.51M | 38.39M |
| Gross Profit | 9.41M | 2.01M | 401.00K | 3.47M | 1.43M | -1.95M |
| EBITDA | -5.70M | -4.17M | -4.23M | -1.98M | -1.30M | 2.01M |
| Net Income | -14.58M | -11.74M | -11.13M | -8.28M | -6.59M | -4.97M |
Balance Sheet | ||||||
| Total Assets | 59.39M | 66.34M | 88.74M | 70.94M | 77.99M | 77.74M |
| Cash, Cash Equivalents and Short-Term Investments | 0.00 | 6.32M | 27.29M | 5.41M | 8.53M | 24.65M |
| Total Debt | 0.00 | 24.03M | 29.82M | 25.32M | 10.74M | 2.64M |
| Total Liabilities | 66.51M | 64.50M | 74.85M | 47.92M | 43.74M | 35.91M |
| Stockholders Equity | -7.12M | 1.84M | 12.62M | 21.77M | 29.64M | 38.78M |
Cash Flow | ||||||
| Free Cash Flow | -8.87M | -10.76M | -5.31M | -6.86M | -7.57M | -5.17M |
| Operating Cash Flow | -7.84M | -9.23M | -3.58M | -4.22M | -1.49M | -3.91M |
| Investing Cash Flow | -2.41M | -1.56M | -1.69M | 562.00K | -12.69M | -2.18M |
| Financing Cash Flow | -3.57M | -10.14M | 26.99M | 459.00K | -1.97M | 11.57M |
B.R.A.I.N. Biotechnology Research and Information Network Technical Analysis
Negative
2.75
Price Trends
2.78
Negative
2.80
Negative
2.69
Positive
Market Momentum
>-0.01
Negative
47.06
Neutral
73.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:BNN, the sentiment is Negative. The current price of 2.75 is below the 20-day moving average (MA) of 2.79, below the 50-day MA of 2.78, and above the 200-day MA of 2.69, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 47.06 is Neutral, neither overbought nor oversold. The STOCH value of 73.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:BNN.
B.R.A.I.N. Biotechnology Research and Information Network Peers Comparison
UnderperformOutperform
Sector (55)
DE:BNN
B.R.A.I.N. Biotechnology Research and Information Network
2.73
0.48
21.33%
DE:CNW
co.don AG
0.01
>-0.01
-25.00%
DE:MDG1
Medigene
0.01
-0.05
-83.33%
DE:HPHA
Heidelberg Pharma AG
2.15
-0.92
-29.97%
DE:FYB
Formycon AG
18.84
-4.01
-17.55%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.